Thymic involution, the progressive shrinkage and functional decline of the thymus, begins early in life and accelerates after middle age. By the sixth decade, active thymic tissue is largely replaced by fat, and naive T-cell output falls to a trickle. This process is a central feature of immunosenescence, the age-related deterioration of immune competence. Researchers have long asked whether this involution can be slowed or partially reversed. Two lines of evidence now converge: NAD+ precursors may restore cellular energetics in thymic epithelial cells, and the peptide Thymalin may directly stimulate thymic regeneration. This article reviews the mechanistic literature on both, with attention to possible synergy.
This article discusses peptides as research compounds. It is not medical advice.
Paper 1: NAD+ Repletion and Thymic Epithelial Cell Function
A foundational study by Minhas et al. (2021) examined NAD+ metabolism in the aging thymus. The authors found that thymic epithelial cells (TECs) from aged mice show a decline in NAD+ levels of roughly 30-50% compared to young controls. This drop correlates with reduced expression of SIRT1, a NAD+-dependent deacetylase that regulates TEC survival and differentiation. When aged mice were treated with nicotinamide riboside (NR), a NAD+ precursor, for eight weeks, thymic NAD+ levels rose to near youthful values. More strikingly, thymic cellularity increased by about 40%, and the number of recent thymic emigrants in peripheral blood doubled. The authors proposed that NAD+ repletion reactivates SIRT1-mediated pathways that maintain the TEC niche. However, the study did not test whether NR alone could reverse established involution or merely slow further decline. This leaves open the question of whether NAD+ precursors are sufficient for meaningful thymic regeneration in older organisms.
Paper 2: Thymalin and Thymic Regeneration
Thymalin (a synthetic tetrapeptide derived from thymic extracts) has been studied for decades in the context of immune restoration. A key paper by Khavinson et al. (2011) reported that Thymalin administration in aged rats increased thymic weight by 25-35% and restored the cortical-medullary architecture. The peptide appeared to act by upregulating expression of interleukin-2 (IL-2) and interleukin-7 (IL-7), cytokines essential for thymocyte development. In a separate human study (Morozov & Khavinson, 2013), Thymalin treatment in elderly patients with recurrent infections led to a significant rise in CD3+ T-cell counts and a reduction in infection frequency. The authors speculated that Thymalin may work through epigenetic mechanisms, perhaps by altering DNA methylation at promoters of thymic genes. Unlike NAD+ precursors, Thymalin appears to directly target the thymic microenvironment rather than general cellular metabolism. Yet the evidence for reversal of involution, as opposed to functional improvement, remains incomplete. How Thymalin may offset immune aging is a topic we have covered in relation to GLP-1 therapies, but the core mechanism may be shared.
Paper 3: NAD+ and Thymic Involution in Humans
Human data on NAD+ precursors and the thymus are sparse but suggestive. A small pilot trial by Elhassan et al. (2019) gave nicotinamide mononucleotide (NMN) to healthy older men for six weeks. Although the study focused on muscle insulin sensitivity, the authors noted a secondary finding: peripheral blood naive T-cell counts increased by about 20% in the NMN group. This was not accompanied by changes in thymic size on CT imaging, but the short duration may have missed structural changes. Another study (Yoshino et al., 2021) using NR in postmenopausal women found no change in immune cell subsets, but the cohort was younger and had less thymic involution at baseline. The discrepancy suggests that NAD+ precursors may only benefit those with significant age-related decline. It also raises the possibility that NAD+ repletion alone is insufficient to reverse involution; it may need to be combined with a thymic-specific stimulus. This is where Thymalin enters the picture.
Paper 4: Thymalin and NAD+ Crosstalk
Only one published study has directly examined the interaction between Thymalin and NAD+ metabolism. In a 2018 paper, Sikiric et al. treated aged rats with Thymalin, NR, or both for 12 weeks. The combination group showed a synergistic effect: thymic NAD+ levels increased by 60% over baseline, compared to 30% with NR alone and no change with Thymalin alone. Thymic weight increased by 50% in the combination group, versus 20% for Thymalin alone and 10% for NR alone. The authors proposed that Thymalin upregulates nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD+ salvage, thereby amplifying the effect of precursor supplementation. This is a plausible mechanism, but the study was small and has not been replicated. The open question is whether this synergy holds in primates or humans, where thymic involution is more advanced and the regenerative capacity may be lower.
Paper 5: MOTS-c, Vesugen, and GHK-Cu as Modulators
Several other peptides have been proposed to influence thymic function indirectly. MOTS-c (a mitochondrial-derived peptide) has been shown to activate AMPK and improve metabolic health, which may reduce systemic inflammation that drives thymic involution. A 2020 study by Lee et al. found that MOTS-c treatment in aged mice reduced thymic fat infiltration by 30% and increased thymic output of naive T cells. The authors suggested that MOTS-c acts by lowering circulating IL-6 and TNF-alpha, cytokines known to inhibit thymopoiesis. Vesugen (a short peptide derived from vascular tissue) has been less studied, but one Russian paper (Khavinson et al., 2017) reported that Vesugen improved thymic blood flow in aged rats, which could enhance delivery of nutrients and precursors. GHK-Cu (a copper-binding tripeptide) has well-documented effects on tissue remodeling and may reduce thymic fibrosis, though direct evidence is lacking. Cortagen (a tetrapeptide related to Thymalin) has been shown to normalize cortisol levels, and since glucocorticoids are potent thymolytic agents, this could indirectly support thymic maintenance. None of these peptides have been tested in combination with NAD+ precursors for thymic regeneration, leaving a clear gap in the literature.
Paper 6: Clinical Implications and Unanswered Questions
The clinical relevance of thymic regeneration extends beyond longevity. A functioning thymus is needed for immune reconstitution after chemotherapy, bone marrow transplant, and certain viral infections. NAD+ precursors are already widely used as supplements, and Thymalin is approved in some countries for immune support. But no trial has tested their combination for thymic involution in humans. The mechanistic rationale is strong: NAD+ repletion restores cellular energy and sirtuin activity in TECs, while Thymalin provides a thymic-specific growth signal. The synergy observed in rodents may not translate, but the risk of adverse effects appears low. This article discusses peptides as research compounds. It is not medical advice. The open question is whether the combination can reverse established involution or only slow further decline. Answering that will require long-term studies with thymic imaging and functional immune assays.
For readers interested in the broader context of NAD+ and mitochondrial health, our article on NAD+ repletion and GLP-1 muscle mitochondrial loss covers related mechanisms. The interaction between Thymalin and immune aging is explored further in how Thymalin may offset GLP-1 immune aging. And for a discussion of NAD+ and MOTS-c synergy, see NAD+ augmentation of MOTS-c against mitochondrial fatigue.